Casodex 150-mg monotherapy has already been approved by the regulatory authorities in five countries, including the UK, Norway, Iceland, South Africa, and Sweden and further approvals are anticipated during 2000 in other countries. Since 1995, a total of 8,113 patients worldwide have been recruited for the EPC Program, and in the U.S., the last patient has just completed therapy. One out of every six men is at lifetime risk for prostate cancer. It is the second most frequently occurring malignancy in American men, after skin cancer, and represents 29 percent of all newly diagnosed cancer cases. Every three minutes a man is diagnosed with prostate cancer in the United States and a life is lost to the disease every 13 minutes.
Prostate cancer is the second leading cause of cancer death among men after lung cancer.
The American Cancer Society estimated 180,400 new cases in the United States during 2000. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer. All rights reserved.